Data Sheet

Product Name:	Fexaramine
Cat. No.:	HY-10912
CAS No.:	574013-66-4
Molecular Formula:	$C_{32}H_{36}N_2O_3$
Molecular Weight:	496.64
Target:	FXR
Pathway:	Metabolic Enzyme/Protease
Solubility:	10 mM in DMSO



BIOLOGICAL ACTIVITY:

Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100–fold increased affinity relative to natural compounds.
IC50 value:
Target:
in vitro: In vitro treatment of CDCA or fexaramine elevated the SHP transcript level and occupancy on secretin promoter [1]. Fexaramine significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal–regulated kinase (ERK) and β–catenin signaling [2]. By mimicking this tissue–selective effect, the gut–restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver [3].

References:

[1]. Lam IP, et al. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G90–7.
[2]. Cho SW, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013 Oct;28(10):2109–21.
[3]. Fang S, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015 Feb;21(2):159–65.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA